MGMT and central nervous system cancer: Additionally, key genetic alterations have been reported in gliomas, such as O6-methylguanine-DNA Methyltransferase (MGMT) promoter methylation, mutations in phosphatase and tensin homolog (PTEN) and tumor protein p53 (TP53), amplification of epidermal growth factor receptor (EGFR), and fusion of the MET tyrosine kinase (MET) gene [6,7].